Most of the molecular-targeted drugs used in the treatment of NSCLC inhibit specific targets that induce cancer evolution [so-called “oncogenic drivers (i.e., EGFR mutation, ALK translocation, ROS1 translocation, and BRAF mutation)”]. This evidence concerns the gene ALK and non-small cell lung carcinoma.